tranScrip Appoints Dr Sally Taylor as Head of Medical Affairs

tranScrip is delighted to announce the appointment of Dr Sally Taylor as Head of Medical Affairs. This strategic move comes as part of tranScrip’s ongoing evolution in Medical Affairs, designed to meet the dynamic challenges of the industry.

With 19 years of extensive experience in Medical Affairs and Clinical Research, Sally brings a wealth of global expertise. A Fellow of the Faculty of Pharmaceutical Medicine, Sally has held leadership roles across the UK, Europe, Canada, and North America. Her impressive career spans diverse therapeutic areas including Vaccines, Oncology, Immunology, Respiratory, Allergy, Dermatology, Osteoporosis, and Cardiovascular Disease. Sally’s track record in transformation, restructuring, and change management—along with her successful leadership in global medical board management—makes her ideally suited to lead tranScrip’s Medical Affairs team into its next chapter of innovation and growth.

Sally commented on her appointment to tranScrip: “I am thrilled to join tranScrip at such an exciting time. The company’s commitment to excellence and its forward-thinking approach to Medical Affairs perfectly align with my passion for driving transformative change in the pharmaceutical industry. I look forward to collaborating with our talented team to enhance our service offering, exploit the synergies with our Commercialisation Services, and ultimately, benefit patients worldwide.”

Sally’s appointment follows tranScrip’s recent strategic enhancements in capabilities with the appointments of John Ivory as Head of Commercialisation and Rosemarie Delaney as Head of Market Access. Medical Affairs and Commercialisation Services will work in tandem to deliver value to our clients and the patients they serve.

Rienk Pypstra, Chief Medical Officer at tranScrip, commented: “We have a proud heritage of driving Medical Affairs at tranScrip, and the time is right to build this further. Sally’s dynamic leadership, coupled with our existing team’s expertise, will allow us not only to tackle the challenges ahead but also to explore new approaches in a rapidly evolving landscape. Sally’s appointment strengthens our purpose to expedite the development and commercialisation of products for the benefit of patients worldwide.”

As tranScrip continues to lead the way from TRANslation to preSCRIPtion, Sally’s leadership marks a significant step forward in our commitment to innovation, operational excellence, and patient-focused outcomes. By leveraging the synergies between Medical Affairs and Commercialisation Services, tranScrip is poised to maximise the value of its clients’ products and contribute meaningfully to global healthcare advancements.

For more insights into our team members, visit Our People.

About tranScrip
tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle – from TRANslation to preSCRIPtion. We exist to enable our clients to maximise the value of their products for the benefit of patients worldwide. For more information, please visit www.transcrip-group.com and follow us on LinkedIn.

Media Contact
Ashton Brooke-Thorne
Senior Marketing Manager
ashton.brooke-thorne@transcrip-group.com